Valuation: COMPASS Pathways plc

Market Cap 1.75B 1.54B 1.42B 1.31B 2.49B 168B 2.54B 17.06B 6.63B 82.14B 6.58B 6.44B 285B P/E 2026 *
-13.7x
P/E 2027 * -9.15x
Enterprise Value 1.33B 1.17B 1.08B 994M 1.88B 127B 1.92B 12.94B 5.03B 62.27B 4.99B 4.88B 216B EV / Sales 2026 *
-
EV / Sales 2027 * 20.4x
Free-Float
25.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: COMPASS Pathways plc

1 day+6.04%
1 week+5.08%
Current month-1.31%
1 month+19.05%
3 months+144.14%
6 months+83.27%
Current year+102.39%
1 week 11.56
Extreme 11.56
14.15
1 month 10.72
Extreme 10.724
15.4
Current year 4.88
Extreme 4.88
15.4
1 year 3.45
Extreme 3.45
15.4
3 years 2.25
Extreme 2.25
15.4
5 years 2.25
Extreme 2.25
49.52
10 years 2.25
Extreme 2.25
61.69
Manager TitleAgeSince
Chief Executive Officer 61 01/08/2022
Director of Finance/CFO 54 01/03/2024
Chief Tech/Sci/R&D Officer 66 01/05/2024
Director TitleAgeSince
Chairman 74 29/03/2024
Director/Board Member 69 01/04/2020
Director/Board Member 67 01/03/2021
Date Insider Type Main position Quantity % Market Cap.
05-27Free

Director

41,119 0.0429%
05-27Free

Director

21,110 0.0220%
05-27Free

Director

21,110 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
+7.51%+5.08%+303.61%+30.94% 1.75B
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.21%+420.77%+597.43% 40.49B
-2.29%+3.83%+23.48%+56.80% 34.35B
-2.13%+0.29%+23.91%-7.13% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.51% - - 16.58B
-2.62%-2.13%+64.96%+120.02% 15.6B
-2.17%+6.65%+104.31%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -0.52%+2.11%+106.53%+107.11% 24.83B
Weighted average by Cap. -1.29%+4.23%+95.38%+133.64%

Financials

2026 *2027 *
Net sales - 61.21M 53.68M 49.56M 45.8M 86.81M 5.86B 88.55M 596M 232M 2.87B 230M 225M 9.96B
Net income -100M -88M -81.25M -75.08M -142M -9.61B -145M -977M -380M -4.7B -377M -369M -16.32B -197M -173M -159M -147M -279M -18.86B -285M -1.92B -745M -9.23B -740M -723M -32.03B
Net Debt -424M -372M -343M -317M -602M -40.61B -614M -4.13B -1.6B -19.87B -1.59B -1.56B -68.99B -504M -442M -408M -377M -715M -48.29B -730M -4.91B -1.91B -23.63B -1.89B -1.85B -82.03B
Logo COMPASS Pathways plc
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Employees
156
Date Price Change Volume
08/07/26 $13.97 +7.51% 7,466,262
07/07/26 $12.99 +1.17% 14,233,189
06/07/26 $12.84 -5.73% 3,202,169
02/07/26 $13.62 +2.48% 4,103,686
01/07/26 $13.29 -6.08% 4,743,546
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.99USD
Average target price
24.47USD
Spread / Average Target
+88.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPS Stock